Get the Stockscreener App
1.645
4.11%
+0.065
Perspective Therapeutics Inc stock is currently priced at $1.645, with a 24-hour trading volume of 979.75K.
It has seen a +4.11% increased in the last 24 hours and a +38.24% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.58 pivot point. If it approaches the $1.67 resistance level, significant changes may occur.
Previous Close:
$1.58
Open:
$1.59
24h Volume:
979.75K
Market Cap:
$927.33M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-20.16
EPS:
-0.0816
Net Cash Flow:
$-37.99M
1W Performance:
+7.52%
1M Performance:
+38.24%
6M Performance:
+532.69%
1Y Performance:
+0.00%
1D Range:
$1.59
$1.66
52W Range:
$0.205
$1.77
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Perspective Therapeutics Inc Stock (CATX) Latest News
Perspective Therapeutics to Participate at Upcoming April Investor Conferences
GlobeNewswire Inc.
Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday?
Benzinga
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
GlobeNewswire Inc.
Perspective Therapeutics Announces $87.4 Million Private Placement
GlobeNewswire Inc.
PTC Therapeutics (PTCT) to Report Q4 Results: Wall Street Expects Earnings Growth
Zacks Investment Research
Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline
Zacks Investment Research
Perspective Therapeutics Inc Stock (CATX) Financials Data
Perspective Therapeutics Inc (CATX) Revenue 2024
CATX reported a revenue (TTM) of $6.96 million for the quarter ending September 30, 2023, a -35.56% decline year-over-year.
Perspective Therapeutics Inc (CATX) Net Income 2024
CATX net income (TTM) was -$46.51 million for the quarter ending December 31, 2023, a -411.25% decrease year-over-year.
Perspective Therapeutics Inc (CATX) Cash Flow 2024
CATX recorded a free cash flow (TTM) of -$37.98 million for the quarter ending December 31, 2023, a -393.89% decrease year-over-year.
Perspective Therapeutics Inc (CATX) Earnings per Share 2024
CATX earnings per share (TTM) was -$0.1716 for the quarter ending December 31, 2023, a -186.00% decline year-over-year.
About Perspective Therapeutics Inc
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
31.99%
0.26%
Cap:
|
Volume (24h):